Endo Health Solutions Management Discusses Q4 2012 Results - Earnings Call ... Seeking Alpha We have an additional quarter of surveillance data that indicates our abuse-deterrent formulation of OPANA ER is abused or misused at a rate that is 80% lower than the generic version of extended-release oxymorphone that were on the market in 2012. We ...
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment